InhibinB as a Marker for Premenstrual Dysphoric Symptoms

抑制素 B 作为经前烦躁症状的标志物

基本信息

批准号：
7232463
负责人：
SHIRLEY ANN HARTLAGE
金额：
$ 9.71万
依托单位：
RUSH UNIVERSITY MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-06-01 至 2009-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7232463
关键词：
Academic Medical Centers Accounting Address Advertising Affect Age Aging American Nurses&apos Association Antibodies Antidepressive Agents Appendix Area Arts Award Biological Biological Markers Blood specimen Categories Characteristics Chicago Cities Clinic Clinical Trials Cognitive Therapy Condition Consultations Country County Hospitals DSM-IV Data Depressive disorder Development Diagnosis Diagnostic Diagnostic and Statistical Manual Disease Doctor of Philosophy Effectiveness Emotional Endocrine Endocrinology Environment Enzyme-Linked Immunosorbent Assay Epidemiologic Studies Ethnic Origin Etiology Evaluation Faculty Female Figs - dietary Finding by Cause Follicle Stimulating Hormone Genetic Head Heart Hispanics Home environment Hormones Hospitals Illinois Immunoassay Infant Infertility Interview Interviewer Knowledge Laboratories Laboratory Study Lead Leadership Length Letters Longevity Luteinizing Hormone Measures Medical Medicine Menstrual cycle Menstruation Minority Modeling Moods National Institute of Mental Health Neighborhoods Numbers Ovarian Ovulation Participant Patients Peptides Perimenopause Personal Satisfaction Personality Pharmaceutical Preparations Pilot Projects Procedures Process Productivity Psychiatric Diagnosis Psychiatry Psychology Public Hospitals Race Rate Reporting Reproductive Endocrinology Research Research Design Research Personnel Resources Risk Factors Role Running Sampling Schools Scientist Seminal Serum Source Specialist Speed Structure Symptoms Talents Testing Training Translating United States Universities Validation Woman Work Writing assay development behavior change college cooking daily functioning day experience health disparity help-seeking behavior inhibin inhibin B medical schools member men metropolitan news premenstrual dysphoric disorder prenatal programs proliferative phase Menstrual cycle racial and ethnic reproductive research clinical testing response skills socioeconomics statistics teacher theories tool urinary

项目摘要

DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed research is to find the causes of severe premenstrual mood and behavior changes, facilitate diagnosis, and speed effective treatment to women seeking help for related disorders. For decades scientists have worked to identify characteristics of the ovarian axis that are associated with premenstrual disorders. Now, results from state-of-the-art endocrine research, the body of knowledge about premenstrual dysphoric disorder (PMDD), and our pilot study converge to suggest that inhibin B, a new marker of ovarian function, may be a biomarker of PMDD. The Specific Aims are to explore (1) the relationship of inhibin B and PMDD; and (2) to determine whether inhibin B differentiates women with and without PMDD after potential confounders are taken into account (the Aberrant Inhibin B Model). Hypotheses will be examined in a sample of 18 to 53-year-old Hispanic, Black, or White menstruating women with or without PMDD (N = 102). To diagnose PMDD according to DSM criteria, participants will rate symptoms and functioning daily for two menstrual cycles, and complete physical and psychiatric evaluations. In each cycle, participants will give blood samples every 3 days after the onset of menstruation until ovulation occurs as determined by home urinary luteinizing hormone test kits. Inhibin B levels will be measured in serum using ELISA. If inhibin B is a marker of PMDD, this may provide clues to the mechanisms of the disorder, premenstrual exacerbations of other conditions, and emotional reactivity in general. Laboratory studies of inhibin B already have been translated into practice aiding diagnosis of various reproductive conditions. Results of this and subsequent studies may facilitate diagnosis of PMDD. New medications targeting endocrine risk factors for premenstrual disorders ultimately may be discovered. The medications may be more efficacious, and more acceptable to women not wanting antidepressants. Data from minorities and perimenopausal women should help scientists address health disparities. Premenstrual dysphoric disorder (PMDD) is one of the most common conditions affecting reproductive age women having a high impact on personal well-being and professional productivity. This study explores the relationship of inhibin B, a new marker of ovarian function, and PMDD. Results are expected to provide clues to the cause of PMDD, facilitate the now burdensome diagnostic process, and lead to new treatments.

描述（由申请人提供）：拟议的研究的广泛长期目标是找到严重的经前情绪和行为改变，促进诊断的原因，并为寻求相关疾病寻求帮助的妇女加快有效治疗。几十年来，科学家一直致力于确定与经前疾病相关的卵巢轴的特征。现在，最先进的内分泌研究，关于经前烦躁不良疾病（PMDD）的知识体系的结果，我们的试点研究表明，抑制素B（卵巢功能的新标志）可能是PMDD的生物标志物。具体目的是探索（1）抑制素B和PMDD的关系；（2）确定抑制素B是否在考虑潜在的混杂因子后是否有和没有PMDD的妇女（异常抑制素B模型）。假设将在18至53岁的西班牙裔，黑色或白色月经妇女的样本中进行检查（n = 102）。为了根据DSM标准诊断PMDD，参与者将对两个月经周期和完整的物理和精神病学评估每天评估症状和功能。在每个周期中，参与者将在月经发作后每3天给出血液样本，直到排卵如家庭尿叶片激素测试试剂盒确定为止。抑制素B水平将在血清中使用ELISA测量。如果抑制素B是PMDD的标记，则可以为该疾病的机制，其他疾病的经结前加重以及一般的情绪反应提供线索。抑制素B的实验室研究已经转化为实践，有助于诊断各种生殖疾病。该研究和随后的研究可能有助于诊断PMDD。最终可能会发现针对内分泌危险因素的新药物最终可能会发现。这些药物可能更有效，并且对不想要抗抑郁药的女性更容易接受。来自少数群体和围绝经期妇女的数据应帮助科学家解决健康差异。经前烦躁不安（PMDD）是影响生殖年龄妇女对个人福祉和职业生产力产生高影响的最常见疾病之一。这项研究探讨了抑制素B（卵巢功能的新标志）和PMDD的关系。预计结果将为PMDD的原因提供线索，促进现在负担重大的诊断过程，并导致新的治疗方法。